2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
pmr score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Non-PMR0–3
  • PMR4–6
  • Non-PMR (US)0–4
  • PMR (US)5–8
Direct Clinical Answer

The 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica calculates classifying inflammatory arthritides and monitoring longitudinal autoimmune disease activity. Key inputs include morning stiffness. Scores guide initiating or optimizing disease-modifying antirheumatic drugs (DMARDs) or targeted biologic therapies. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Classifies polymyalgia rheumatica by expert consensus recommendations using clinical and optionally ultrasonographic criteria

Clinical Indication

The 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica is indicated for bedside clinical practice to support Classifies polymyalgia rheumatica by expert consensus recommendations using clinical and optionally ultrasonographic criteria. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with inflammatory arthritis, systemic lupus erythematosus, systemic vasculitis, or autoimmune connective tissue disorders. Clinical application is indicated across Rheumatology clinics, connective tissue disease units, and academic medical centers.

Limitations & Contraindications

Elevated erythrocyte sedimentation rate (ESR) and CRP are non-specific acute phase reactants that can reflect occult systemic infection.

Clinical Pearls & Action Plan

Serological autoantibody testing must strictly correlate with inflammatory joint patterns and objective synovial pathology. Guideline pearl: Lower specificity for distinguishing PMR from seronegative rheumatoid arthritis.

Formula & Variables:

Score = Morning stiffness (0-2) + Hip pain/limited ROM (0-1) + Absence RF/ACPA (0-2) + Absence pain other joints (0-1) + Shoulder/hip ultrasound (0-1) + Both shoulders ultrasound (0-1)

Input Parameters

NameTypeRequiredDescription
morning_stiffnessstringYesDuration of morning stiffness
hip_pain_limited_romstringYesHip pain or limited range of motion
rf_or_acpastringYesRheumatoid factor (RF) or anti-citrullinated peptide antibody (ACPA)
other_joint_painstringYesPain in other joints
ultrasound_shoulder_hipstringNoAt least one shoulder with specific findings and one hip with synovitis (ultrasound)
ultrasound_both_shouldersstringNoBoth shoulders with specific findings (ultrasound)

Score Interpretation & Guidance

RangeStageDescription
0–3Non-PMRDoes not classify as PMR (without ultrasound)
4–6PMRClassifies as PMR (without ultrasound)
0–4Non-PMR (US)Does not classify as PMR (with ultrasound)
5–8PMR (US)Classifies as PMR (with ultrasound)

Evidence-Based References (EBM)

  • Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484-92.
  • Mackie SL, Koduri G, Hill CL, et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. RMD Open. 2015;1(1):e000100.

Related calculators